Literature DB >> 14711900

Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome.

Lara S Shekerdemian1, Hanne B Ravn, Daniel J Penny.   

Abstract

There has been recent interest in the use of the phosphodiesterase-5 inhibitor sildenafil for treating pulmonary hypertension. We examined the interaction between inhaled nitric oxide (iNO) and i.v. sildenafil in 12 piglets with acute pulmonary hypertension and lung injury secondary to meconium aspiration. Six animals (controls) received no intervention after meconium instillation, and six received iNO (20 ppm) from 120 min, with the addition at 240 min of an i.v. sildenafil infusion (2 mg/kg over 2 h). Meconium instillation increased mean pulmonary artery (PA) pressure from 16.0 +/- 3.1 to 24.8 +/- 4.6 mm Hg (p < 0.01) and pulmonary vascular resistance (PVR) from 0.047 +/- 0.008 to 0.089 +/- 0.027 mm Hg. ml(-1). min(-1). kg(-1) (p < 0.01). Oxygenation index increased from 3 +/- 0.8 to 8.3 +/- 3.0 (p < 0.01). There were no further changes beyond 120 min in controls. iNO reduced PA pressure and PVR to baseline values, without influencing oxygenation. The addition of sildenafil further reduced PA pressure, tended to increase the cardiac output, and reduced PVR from 0.049 +/- 0.02 to 0.028 +/- 0.01 mm Hg. ml(-1). min(-1). kg(-1) (p < 0.05). Sildenafil lowered the systemic blood pressure and systemic vascular resistance and produced profound arterial hypoxemia, reducing arterial Po(2) from 69 +/- 23 mm Hg to 49 +/- 15 mm Hg, despite substantial increases first in inspired oxygen fraction and subsequently in mean airway pressures. Consequently, the oxygenation index increased by 13.9 +/- 4.8 (p = 0.01). When given in addition to iNO, sildenafil at a dose of >0.5 mg/kg produced profound pulmonary vasodilation, but this was coupled with an unacceptable deterioration in oxygenation and systemic vasodilation in this model of pulmonary hypertension with acute parenchymal lung disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711900     DOI: 10.1203/01.PDR.0000112033.81970.C2

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  14 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 2.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Nitric oxide and beyond: new insights and therapies for pulmonary hypertension.

Authors:  R H Steinhorn
Journal:  J Perinatol       Date:  2008-12       Impact factor: 2.521

Review 4.  Neonatal pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2010-03       Impact factor: 3.624

Review 5.  Persistent pulmonary hypertension of the newborn: pathogenesis, etiology, and management.

Authors:  Enrique M Ostrea; Esterlita T Villanueva-Uy; Girija Natarajan; Herbert G Uy
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  Therapeutic approaches using nitric oxide in infants and children.

Authors:  Robin H Steinhorn
Journal:  Free Radic Biol Med       Date:  2011-01-13       Impact factor: 7.376

Review 7.  Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension.

Authors:  Kathryn N Farrow; Robin H Steinhorn
Journal:  Handb Exp Pharmacol       Date:  2011

8.  Intravenous tezosentan improves gas exchange and hemodynamics in acute lung injury secondary to meconium aspiration.

Authors:  Ralf Geiger; Axel Kleinsasser; Stephan Meier; Nikolaus Neu; Werner Pajk; Victoria Fischer; Benedict Treml; Joerg I Stein; Alexander Loeckinger
Journal:  Intensive Care Med       Date:  2007-09-27       Impact factor: 17.440

Review 9.  Pharmacologic strategies in neonatal pulmonary hypertension other than nitric oxide.

Authors:  Satyan Lakshminrusimha; Bobby Mathew; Corinne L Leach
Journal:  Semin Perinatol       Date:  2016-01-14       Impact factor: 3.300

Review 10.  Inhaled NO in the experimental setting.

Authors:  Nicolas F M Porta; Robin H Steinhorn
Journal:  Early Hum Dev       Date:  2008-10-22       Impact factor: 2.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.